Skip to Content
  • Previous Rank
    254
  • Revenues ($M)
    $13,003.00
  • Revenue Percent Change
    15.8%
  • Profits ($M)
    $2,940.00
  • Profits Percent Change
    47.1%
  • Assets ($M)
    $30,141.00
  • Employees
    7,467
  • Market Value — as of March 29, 2018 ($M)
    $67,101.60

The biopharmaceutical company is the maker of Thalomid and various other drugs that treat multimple myeloma, inflammatory diseases, and various forms of cancer.

Company Info

CEO
Mark J. Alles
CEO Title
Chairman & Chief Executive Officer
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Summit, N.J.
Websitehttp://www.celgene.com
Years on Fortune 500 List7
Employees7,467
Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Purchase Now

Celgene Rank History

placeholder

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$13,003.0015.8%
Profits ($M)$2,940.0047.1%
Assets ($M)$30,141.00-
Total Stockholder Equity ($M)$6,921.00-
Market Value — as of March 29, 2018 ($M)$67,101.60-

Profit Ratios

Profit as % of Revenues22.6%
Profits as % of Assets9.8%
Profits as % of Stockholder Equity42.5%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)3.64
EPS % Change (from 2016)46.2%
EPS % Change (5 year annual rate)17.1%
EPS % Change (10 year annual rate)29.7%

Total Return

Total Return to Investors (2017)-9.8%
Total Return to Investors (5 year, annualized)21.6%
Total Return to Investors (10 year, annualized)16.3%